© Tumisu/Pixabay.com

After BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%.

Picture: ©Evotec

Evotec SE is set to expand the company’s existing campus in Milton Park/Abingdon, UK, into a major, fully-integrated drug discovery and development centre.

©Aymanejed/Pixabay.com

Pfizer and Biontech SE have reached an agreement with the European Commission to supply 200 million doses of their mRNA-based COVID-19 vaccine candidate.

Source: Global Bioeconomy Summit

More than 1,800 attendees already registered for the Global Bioeconomy Summit 2020. The conference takes place virtually from November 16 to 20. 

© BioNTech SE

Interim data on BioNtech’s/Pfizer’s COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA.

Arek Socha/Pixabay.com

Swiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedica’s experimental kidney drug ANG-3777.

picture: Eppendorf AG

Most Compact System for Early Stage Processes – The Eppendorf DASbox Mini Bioreactor System, with its small working volume, compact design, as well as advanced control and information management options is ideal for research and early development processes.

Claire Skentelbery, well known and connected in the European biotech community, will be the new Director General of EuropaBio. She will join the EuropaBio team at the end of November.

Melanie Leveridge takes over the lead of the European Laboratory Research & Innovation Group (ELRIG) UK to drive further collaboration between academia and biopharma industry.

Operational Strength of Richter-Helm /picture: ©Richter-Helm

CDMO Continuous growth and diversification of the biotechnology market for pharmaceutical production have been recorded in the past years. It is expected that both trends, growth and diversification from blockbusters towards niche products, will continue. What requirements are derived from customers’ point of view and what are the advantages of Richter-Helm as a successful CDMO to fulfil such needs?